Clicky

Atossa Genetics Inc.(ATOS)

Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.


Keywords: Medicine Cancer Breast Cancer Cancer Treatment Genetics Diagnostic Tests Risk Assessment Breast Implant Breast Surgery Assessment Products Hereditary Cancers Breast Cancer Awareness

Home Page: www.atossatherapeutics.com

ATOS Technical Analysis

107 Spring Street
Seattle, WA 98104
United States
Phone: 206 588 0256


Officers

Name Title
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & Pres
Mr. Kyle Guse CPA, Esq., CPA CFO, Gen. Counsel & Sec.
Ms. Heather Rees VP of Fin. & Accounting
Ms. Delly Behen P.H.R. VP of Admin. & HR
Ms. Janet Rose Rea MSPH, RAC Sr. VP of Regulatory, Quality & Clinical Affairs
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6275
Price-to-Sales TTM: 0
IPO Date: 2012-11-08
Fiscal Year End: December
Full Time Employees: 6
Back to stocks